Home
Live Updates
ImPrint Biomarker Predicts Immunotherapy Response in Patients With HR+/HER2– Breast Cancer : comparemela.com
ImPrint Biomarker Predicts Immunotherapy Response in Patients With HR+/HER2– Breast Cancer
Denise M. Wolf, PhD, discusses the methods used to conduct the I-SPY2 study and the implications that immune biomarkers could have on selecting treatment for patients with hormone receptor–positive, HER2-negative breast cancer in the future.
Related Keywords
San Francisco ,
California ,
United States ,
Denisem Wolf ,
Michaelj Campbell ,
,
Department Of Laboratory Medicine ,
University Of California ,
Laboratory Medicine ,
Cancer Cell ,
Investigational Device Exemption ,
Phd ,
Ispy2 ,
Breast Cancer ,
Asco Annual Meeting ,
comparemela.com © 2020. All Rights Reserved.